Symbiotec Pharmalab sets Rs 938-988 band for Rs 1,757 crore IPO

The Development

Symbiotec Pharmalab Limited, an Indore-based active pharmaceutical ingredient (API) maker, has reached the launch stage of its initial public offering. The company filed its red herring prospectus (RHP), dated August 18, 2026, with the Registrar of Companies, Madhya Pradesh at Gwalior, and the document is on record with SEBI. Per the RHP, the offer is a book-built issue aggregating up to Rs 1,757 crore, combining a fresh issue of up to Rs 150 crore and an offer for sale of up to Rs 1,607 crore.

The bid/offer programme in the RHP sets anchor investor bidding for Friday, August 21, 2026, with the issue opening for public subscription on Monday, August 24, 2026 and closing on Thursday, August 27, 2026. The price band has been fixed at Rs 938 to Rs 988 per share of face value Rs 2; the RHP's own weighted-average-cost table lists an acquisition-price range topping out at Rs 988. The anchor allocation, reported at Rs 526.20 crore, was first covered by The Economic Times. The equity shares are proposed to be listed on the NSE and BSE, with BSE as the designated stock exchange.

The Company

Per the RHP, Symbiotec Pharmalab describes itself as a "research and development-driven, science-based" pharmaceutical and biotechnology company operating across organic chemistry, biotechnology and complex injectables. It manufactures active pharmaceutical ingredients and intermediates and operates as a contract development and manufacturing organisation (CDMO). The company discloses global leadership in corticosteroid and steroidal-hormone APIs, and reports over 50 domestic and over 150 export customers as of March 31, 2026, serving more than 200 customers across over 40 countries.

On financials, the company discloses revenue from operations of Rs 869.15 crore in Fiscal 2026, up from Rs 751.55 crore in Fiscal 2025 and Rs 716.25 crore in Fiscal 2024. Profit after tax was Rs 109.90 crore in Fiscal 2026, against Rs 96.79 crore in Fiscal 2025 and Rs 100.06 crore in Fiscal 2024, per the restated consolidated statements. EBITDA for Fiscal 2026 stood at Rs 231.97 crore and net worth at Rs 1,158.64 crore, the RHP states. Revenue from external customers outside India was 67.04% of revenue from operations in Fiscal 2026. The promoters are Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP.

The Offer Structure

The offer combines a fresh issue of up to Rs 150 crore and an offer for sale of up to Rs 1,607 crore, per the RHP. The selling shareholders are Satwani Holdings LLP (up to Rs 144 crore), Rosewood Investments (up to Rs 988 crore) and India Business Excellence Fund - III (up to Rs 475 crore). Because the bulk of the issue is an offer for sale, the company will not receive those proceeds; only the fresh-issue money accrues to Symbiotec.

The stated objects of the fresh issue are the prepayment or repayment of up to Rs 112.50 crore of borrowings - the company discloses standalone fund-based borrowings of Rs 349.78 crore as at March 31, 2026 - and general corporate purposes. The price band is Rs 938 to Rs 988 per share, with the minimum application being one lot as specified in the price band advertisement. Readers working through the arithmetic of an allotment can use Oquilia's lumpsum calculator or CAGR calculator, and find prior coverage on the Oquilia news desk. The book-running lead managers are JM Financial, Avendus Capital, Motilal Oswal Investment Advisors and Nomura Financial Advisory and Securities (India); MUFG Intime India is the registrar to the offer.

Risk Factors

The RHP lists ten internal risk factors. Among them, the company discloses heavy dependence on APIs, which made up 96.07% of revenue from operations in Fiscal 2026, with the top five APIs contributing 67.27%. The RHP notes that any reduction in demand for these products, or disruption in production, could adversely affect the business.

Among the risk factors the company discloses, its manufacturing facilities and R&D centres are all located in Madhya Pradesh, so adverse developments in that state could affect operations. The RHP also flags customer concentration - the top ten customers accounted for 57.59% of revenue from sale of products in Fiscal 2026 - and export exposure, with revenue from outside India at 67.04% of operations and United States revenue at 13.12%, leaving the company sensitive to tariffs or anti-outsourcing measures. The company further discloses that its statutory auditors' examination report on the restated consolidated statements includes certain modifications. These are the company's own disclosures, not an assessment by this desk.

What Happens Next

With the price band and anchor book in place, the standard mechanics run as follows: the anchor allocation was completed a working day before opening, the three-day public subscription window runs from August 24 to August 27, and category-wise bid data for qualified institutional buyers, non-institutional investors and retail investors will be published by the exchanges as the issue progresses. Applications are made through the ASBA and UPI framework, per the RHP, with the UPI mandate end time set at 5:00 p.m. on the closing date.

After the window closes, the basis of allotment is finalised with the registrar, MUFG Intime India, followed by refunds or the unblocking of application funds and the credit of shares to demat accounts. The equity shares are then scheduled to list on the NSE and BSE, with the exact listing date to be confirmed by an exchange notice. Each of these steps is a process milestone on the official record, not a signal about demand or price.

FAQ

Should I apply for this IPO?

Oquilia does not make recommendations. This report is informational and is not investment advice or a recommendation to subscribe. The RHP, including the complete risk-factors section, is available on SEBI's website and the exchanges - read it directly before making any decision.

What is the price band and issue size?

The price band is Rs 938 to Rs 988 per share of face value Rs 2, per the RHP and the price band advertisement. The total offer aggregates up to Rs 1,757 crore, comprising a fresh issue of up to Rs 150 crore and an offer for sale of up to Rs 1,607 crore by the selling shareholders.

When does the issue open and close?

Per the RHP's bid/offer programme, anchor bidding took place on August 21, 2026, the issue opens on August 24, 2026 and closes on August 27, 2026. The UPI mandate end time is 5:00 p.m. on the closing date.

How is the basis of allotment decided?

For a book-built issue, allotment follows SEBI's ICDR framework once subscription closes. The registrar, MUFG Intime India, finalises the basis of allotment category-wise; where the retail portion is oversubscribed, allotment is by lottery for one lot each. The exchange and registrar notices carry the final schedule.

Where can I read the RHP?

The red herring prospectus is available on SEBI's website and on the NSE and BSE portals, as well as on the company and lead-manager websites. The abridged prospectus on SEBI's public-issues filings page carries the salient features.

This report is based on the red herring prospectus filed with SEBI by Symbiotec Pharmalab Limited. The price band and anchor allocation were surfaced via coverage in The Economic Times.